Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 1/2017

Open Access 01-01-2017 | Original Paper

Economic burden of toxicities associated with treating metastatic melanoma in eight countries

Authors: Elizabeth Wehler, Zhongyun Zhao, S. Pinar Bilir, Julie Munakata, Beth Barber

Published in: The European Journal of Health Economics | Issue 1/2017

Login to get access

Abstract

Background

Information on costs of managing adverse events (AEs) associated with current treatments in metastatic melanoma is limited. This study estimates costs of AEs in eight countries: Australia (AU), Canada (CA), France (FR), Germany (GE), Italy (IT), the Netherlands (NL), Spain (ES), and the UK.

Methods

A literature search was conducted to identify grade 3/4 AEs from product label, published trials, conference abstracts, and treatment guidelines. Resource utilization for the management of each type of AE was determined via interviews with 5 melanoma clinicians in each country. Outpatient and inpatient costs were estimated for each type of AE using country-specific tariffs or government/published sources.

Results

In outpatient settings, the most costly AEs per incident included cutaneous squamous cell carcinoma (CSCC) (€1063, £720; NL/UK), anemia (€1443, €1329, €1285; ES/IT/FR), peripheral neuropathy (€1289; ES), and immune-related diarrhea (AUS$1,121; AU). In inpatient settings, the most costly AEs per hospitalization included hypophysitis (€10,265; €5316; CAN$9735; AUS$7231: ES/FR/CA/AU), dyspnea (€9077; GE), elevated liver enzymes (€6913, CAN$8030, AUS$6594; FR/CA/AU), CSCC (CAN$8934; CA), peripheral neuropathy (€6977, €4144, CAN$9472; NL/ES/CA), and diarrhea (£4284, €4113; UK/ES).

Conclusions

Costs of managing AEs can be significant, and thus effective treatments with lower rates of severe AEs would be valuable.
Appendix
Available only for authorised users
Literature
1.
Erdmann, F., Lortet-Tieulen, J., Schuz, J., Zeeb, H., Greinert, R., Breitbart, E.W., Bray, F.: International trends in the incidence of malignant melanoma 1953–2008: are recent generations at higher or lower risk? Int. J. Cancer 132, 385–400 (2013)CrossRefPubMed
2.
Whiteman, D., Green, A.: Epidemiology of malignant melanoma. In: Dummer, R., Pittelkow, M.R., Iwatsuki, K., Green, A., Elwan, N.M. (eds.) Skin cancer: a world-wide perspective, pp. 13–26. Springer, Berlin Heidelberg (2011)
3.
Bilitou, A., Zhao, Z., Barber, B.L., Claptaon, G.S., Saltman, D.: Patterns of pharmaceutical therapy in advanced melanoma. J. Clin. Oncol. 31(15_suppl), e20014 (2013)
4.
5.
Dean, E., Lorigan, P.: Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. Expert Rev. Anticancer Ther. 12, 1437–1448 (2012)CrossRefPubMed
6.
7.
Maverakis, E., Cornelius, L.A., Bowen, G.M., Phan, T., Patel, F.B., Fitzmaurice, S., He, Y., Burrall, B., Duong, C., Kloxin, A.M., Sultani, H., Wilken, R., Martinez, S.R., Patel, F.: Metastatic melanoma: a review of current and future treatment options. Acta Derm. Venereol. 95, 516–524 (2015)CrossRefPubMed
8.
Hodi, F.S., O’Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., Akerley, W., van den Eetwegh, A.J., Lutzky, J., Lorigan, P., Vaubel, J.M., Linette, G.P., Hogg, D., Ottensmeier, C.H., Lebbe, C., Peschel, C., Quirt, I., Clark, J.I., Wolchok, J.D., Weber, J.S., Tian, J., Yellin, M.J., Nichol, G.M., Hoos, A., Urba, W.J.: Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010)CrossRefPubMedPubMedCentral
9.
Garbe, C., Terheyden, P., Keilholz, U., Kolbl, O., Hauschild, A.: Treatment of melanoma. Dtsch Arztebl Int. 105, 845–851 (2008)PubMedPubMedCentral
10.
11.
12.
Marsden, J.R., Newton-Bishop, J.A., Burrows, L., Cook, M., Corrie, P.G., Cox, N.H., Gore, M.E., Lorigan, P., MacKie, R., Nathan, P., Peach, H., Powell, B., Walker, C.: British Association of Dermatologists clinical standards unit: revised UK guidelines for the management of cutaneous melanoma 2010. Br. J. Dermatol. 163, 238–256 (2010)CrossRefPubMed
13.
Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Spatz, A., Grob, J.J., Malvehy, J., Newton-Bishop, J., Stratigos, A., Pehamberger, H., Eggermont, A.: Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur. J. Cancer 46, 270–283 (2010)CrossRefPubMed
14.
Dummer, R., Hauschild, A., Guggenheim, M., Jost, L., Pentheroudakis, G.: ESMO guidelines working group: melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(suppl 5), 194–197 (2010)CrossRef
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
Maio, M., Ascierto, P., Testori, A., Ridolfi, R., Bajetta, E., Queirolo, P., Guida, M., Romanini, A., Chiarion-Sileni, V., Pigozzo, J., Di Giacomo, A.M., Calandriello, M., Didoni, G., van Baardewijk, M., Konto, C., Lucioni, C.: The cost of unresectable stage III or stage IV melanoma in Italy. J. Exp. Clin. Cancer Res. (2012). doi:10.​1186/​1756-9966-31-91
45.
Chang, C., Schabert, V., Munakata, J., Donga, P., Abhyankar, S., Reyes, C.M., Yim, Y.M.: Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Res. 25, 312–320 (2015)CrossRefPubMed
46.
Hauschild, A., Grob, J.J., Demidov, L.V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C.U., Miller Jr, W.H., Kaempgen, E., Martin-Algarra, S., Karaszewska, B., Mauch, C., Chiarion-Sileni, V., Martin, A.M., Swann, S., Haney, P., Mirakhur, B., Guckert, M.E., Goodman, V., Chapman, P.B.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358–365 (2012)CrossRefPubMed
47.
Patel, P.M., Suciu, S., Mortier, L., Kruit, W.H., Robert, C., Schadendorf, D., Trefzer, U., Punt, C.J., Dummer, R., Davidson, N., Becker, J., Conry, R., Thompson, J.A., Hwu, W.J., Engelen, K., Agarwala, S.S., Keilholz, U., Eggermont, A.M., Spatz, A.: EORTC melanoma group: extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur. J. Cancer 47, 1476–1483 (2011)CrossRefPubMed
48.
Avril, M.F., Aamdal, S., Grob, J.J., Hauschild, A., Mohr, P., Bonerandi, J.J., Weichenthal, M., Neuber, K., Bieber, T., Gilde, K., Guillem Porta, V., Fra, J., Bonneterre, J., Saiag, P., Kamanabrou, D., Pehamberger, H., Sufliarsky, J., Gonzalez Larriba, J.L., Scherrer, A., Menu, Y.: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J. Clin. Oncol. 15, 1118–1125 (2004)CrossRef
49.
Tarhini, A.A., Kirkwood, J.M., Goodling, W.E., Cai, C., Agarwala, S.S.: Durable complete responses with high-dose bolas interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J. Clin. Oncol. 25, 3802–3807 (2007)CrossRefPubMed
50.
Hersh, E.M., O’Day, S.J., Powderly, J., Khan, K.D., Pavlick, A.C., Cranmer, L.D., Samlowski, W.E., Nichol, G.M., Yellin, M.J., Weber, J.S.: A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest. New Drugs 29, 489–498 (2011)CrossRefPubMed
51.
Flaherty, K.T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L.V., Hassel, J.C., Rutkowski, P., Mohr, P., Dummer, R., Trefzer, U., Larkin, J.M., Utikal, J., Dreno, B., Nyakas, M., Middleton, M.R., Becker, J.C., Casey, M., Sherman, L.J., Wu, F.S., Ouellet, D., Martin, A.M., Patel, K., Schadendorf, D.: METRIC Study Group: improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107–114 (2012)CrossRefPubMed
52.
Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O’Day, S.J., Sosman, J.A., Kirkwood, J.M., Eggermont, A.M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R.J., Flaherty, K.T., McArthur, G.A.: BRIM-3 study group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011)CrossRefPubMedPubMedCentral
53.
Sosman, J.A., Kim, K.B., Schuchter, L., Gonzalez, R., Pavlick, A.C., Weber, J.S., McArthur, G.A., Hutson, T.E., Moschos, S.J., Flaherty, K.T., Hersey, P., Kefford, R., Lawrence, D., Puzanov, I., Lewis, K.D., Amaravadi, R.K., Chmielowski, B., Lawrence, H.J., Shyr, Y., Ye, F., Li, J., Nolop, K.B., Lee, R.J., Joe, A.K., Ribas, A.: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707–714 (2012)CrossRefPubMedPubMedCentral
Metadata
Title
Economic burden of toxicities associated with treating metastatic melanoma in eight countries
Authors
Elizabeth Wehler
Zhongyun Zhao
S. Pinar Bilir
Julie Munakata
Beth Barber
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 1/2017
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-015-0757-y

Other articles of this Issue 1/2017

The European Journal of Health Economics 1/2017 Go to the issue

Original Paper

A short note on measuring subjective life expectancy: survival probabilities versus point estimates

Original Paper

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study

Original Paper

Why trash don’t pass? pharmaceutical licensing and safety performance of drugs

Original Paper

Competition and quality in a physiotherapy market with fixed prices

Editorial

Priorities in the Polish health care system

Original Paper

An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting